| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1009439533 |
| P356 | DOI | 10.1038/ONC.2011.124 |
| P953 | full work available at URL | https://doi.org/10.1038/onc.2011.124 |
| https://europepmc.org/articles/PMC4482257 | ||
| https://europepmc.org/articles/PMC4482257?pdf=render | ||
| https://www.nature.com/articles/onc2011124 | ||
| https://www.nature.com/articles/onc2011124.pdf | ||
| P932 | PMC publication ID | 4482257 |
| P698 | PubMed publication ID | 21499302 |
| P5875 | ResearchGate publication ID | 51057146 |
| P50 | author | Pietro Rizza | Q56516232 |
| Daniela Bonofiglio | Q56516237 | ||
| Stefania Catalano | Q56516243 | ||
| Ines Barone | Q59688868 | ||
| Luca Gelsomino | Q87908276 | ||
| Suzanne A W Fuqua | Q88598563 | ||
| P2093 | author name string | C. Giordano | |
| S. Andò | |||
| S. Panza | |||
| D. Vizza | |||
| P2860 | cites work | Identification of a nuclear receptor for bile acids | Q22010058 |
| Bile acids: natural ligands for an orphan nuclear receptor | Q22010063 | ||
| HER-2 gene amplification can be acquired as breast cancer progresses | Q24563115 | ||
| Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment | Q24801967 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer | Q46586619 | ||
| Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells | Q46853309 | ||
| Insulin-like growth factor-I, regulating aromatase expression through steroidogenic factor 1, supports estrogen-dependent tumor Leydig cell proliferation | Q53529918 | ||
| Optimising the Role of Herceptin in Breast Cancer. Symposium proceedings. Monte Carlo, June 19-21, 2000 | Q95800680 | ||
| The bile acid receptor FXR is a modulator of intestinal innate immunity | Q28116925 | ||
| Oncogenic kinase signalling | Q28189493 | ||
| Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study | Q28283241 | ||
| LXRS and FXR: the yin and yang of cholesterol and fat metabolism | Q28295718 | ||
| Identification of a nuclear receptor that is activated by farnesol metabolites | Q28302684 | ||
| Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α | Q28308069 | ||
| Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells | Q28571177 | ||
| A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells | Q29547557 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Amplification of growth regulatory genes in intraductal breast cancer is associated with higher nuclear grade but not with the progression to invasiveness. | Q30986520 | ||
| Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway | Q33583914 | ||
| Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer | Q34181456 | ||
| Measurement of steroid hormone receptors in breast cancer patients on tamoxifen | Q34345668 | ||
| Biology of HER2 and its importance in breast cancer | Q34428745 | ||
| Characterization of the promoter region of the human c-erbB-2 protooncogene | Q34633898 | ||
| Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element | Q34790389 | ||
| Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. | Q35786706 | ||
| Tamoxifen--what next? | Q35841960 | ||
| FXR as a novel therapeutic target for vascular disease | Q35987252 | ||
| Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy | Q35991001 | ||
| Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance | Q36860992 | ||
| Enhancing the efficacy of hormonal agents with selected targeted agents | Q37533801 | ||
| Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. | Q38300264 | ||
| Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor | Q38313790 | ||
| The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis | Q38315886 | ||
| Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters | Q38337562 | ||
| Resistance to tamoxifen‐induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer | Q39411673 | ||
| G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells | Q39800227 | ||
| Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation | Q40164157 | ||
| Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells | Q40195766 | ||
| The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression | Q40218920 | ||
| Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. | Q40383001 | ||
| The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation | Q40427640 | ||
| Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance | Q40536641 | ||
| Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer | Q40544950 | ||
| Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells | Q40670668 | ||
| Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer | Q41090487 | ||
| Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. | Q43607758 | ||
| Use of dominant negative nuclear receptors to study xenobiotic-inducible gene expression in primary cultured hepatocytes | Q44356501 | ||
| Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients | Q44825601 | ||
| HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study | Q45050365 | ||
| Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase | Q45309214 | ||
| P433 | issue | 39 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell growth | Q189159 |
| tamoxifen | Q412178 | ||
| Erb-b2 receptor tyrosine kinase 2 | Q415271 | ||
| P304 | page(s) | 4129-4140 | |
| P577 | publication date | 2011-04-18 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression | |
| P478 | volume | 30 |
| Q35112392 | AR collaborates with ERα in aromatase inhibitor-resistant breast cancer. |
| Q36602170 | Activated FXR Inhibits Leptin Signaling and Counteracts Tumor-promoting Activities of Cancer-Associated Fibroblasts in Breast Malignancy |
| Q42149700 | Bile acids induce apoptosis selectively in androgen-dependent and -independent prostate cancer cells |
| Q36979218 | CCAR1 5' UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance. |
| Q39128970 | Dithiiranylmethyloxy azaxanthone shows potent anti-tumor activity via suppression of HER2 expression and HER2-mediated signals in HER2-overexpressing breast cancer cells |
| Q37690691 | Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines |
| Q61804895 | Expression signatures and roles of microRNAs in inflammatory breast cancer |
| Q37376356 | FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression |
| Q35551981 | Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma |
| Q37448273 | Farnesoid X receptor ligand CDCA suppresses human prostate cancer cells growth by inhibiting lipid metabolism via targeting sterol response element binding protein 1. |
| Q28272905 | Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update |
| Q36559266 | Identifying protein interaction subnetworks by a bagging Markov random field-based method. |
| Q54473491 | Inhibition of Leydig tumor growth by farnesoid X receptor activation: the in vitro and in vivo basis for a novel therapeutic strategy. |
| Q26764743 | Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancer |
| Q37428836 | Lithocholic acid induces endoplasmic reticulum stress, autophagy and mitochondrial dysfunction in human prostate cancer cells. |
| Q91807107 | Liver- and Microbiome-derived Bile Acids Accumulate in Human Breast Tumors and Inhibit Growth and Improve Patient Survival |
| Q38014901 | Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators |
| Q39259280 | Mollugin inhibits proliferation and induces apoptosis by suppressing fatty acid synthase in HER2‐overexpressing cancer cells |
| Q34465146 | Src-Mediated Cross-Talk between Farnesoid X and Epidermal Growth Factor Receptors Inhibits Human Intestinal Cell Proliferation and Tumorigenesis |
| Q53270421 | Synergistic growth inhibition of human hepatocellular carcinoma cells by acyclic retinoid and GW4064, a farnesoid X receptor ligand |
| Q42253372 | Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors |
| Q38984903 | Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth |
| Q61810783 | The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma |
| Q99555913 | The Role of PPARγ Ligands in Breast Cancer: From Basic Research to Clinical Studies |
| Q35665486 | The role of bile acids in reducing the metabolic complications of obesity after bariatric surgery: a systematic review. |
| Q36640852 | The transcriptional co-factor RIP140 regulates mammary gland development by promoting the generation of key mitogenic signals |
| Q33648565 | Three measurable and modifiable enteric microbial biotransformations relevant to cancer prevention and treatment |
| Q48111857 | miRNA expression profiling of inflammatory breast cancer identifies a 5‐miRNA signature predictive of breast tumor aggressiveness |
Search more.